Systemic Treatment Options for Atopic Dermatitis

Video content above is provided by the following:

• Describe your approach to initiating systemic treatment in patients with AD. At what point do you consider systemic treatment for your patients?
• Does your approach differ based on patient age or other factors?
• Briefly discuss the systemic agents that are currently FDA-approved for AD, including how they work to address itch and skin lesions, as well as efficacy and safety data.
  • Dupilumab, lebrikizumab, tralokinumab, nemolizumab
  • Abrocitinib, upadacitinib